4-Methylmorpholine → (3R)-6-Cyclohexyl-N-hydroxy-3-(3-{[3-(4-morpholinyl)-1-azetidinyl]carbonyl}-1,2,4-oxadiazol-5-yl)hexanamide

HRID 1279775ノート

反応式

HRID 1279775 の反応式
FC(F)(F)C(O)=O.[CH:8]1([CH2:14][CH2:15][CH2:16][C@@H:17]([C:22]2[O:26][N:25]=[C:24]([C:27]([N:29]3[CH2:32][CH:31]([N:33]4[CH2:38][CH2:37][O:36][CH2:35][CH2:34]4)[CH2:30]3)=[O:28])[N:23]=2)[CH2:18][C:19]([OH:21])=O)[CH2:13][CH2:12][CH2:11][CH2:10][CH2:9]1.CN1CCOCC1.ClC(OCC(C)C)=O.Cl.[NH2:55][OH:56]>CN(C)C=O>[CH:8]1([CH2:14][CH2:15][CH2:16][C@@H:17]([C:22]2[O:26][N:25]=[C:24]([C:27]([N:29]3[CH2:32][CH:31]([N:33]4[CH2:34][CH2:35][O:36][CH2:37][CH2:38]4)[CH2:30]3)=[O:28])[N:23]=2)[CH2:18][C:19]([NH:55][OH:56])=[O:21])[CH2:9][CH2:10][CH2:11][CH2:12][CH2:13]1

参加物

6

反応物 4

HCID 79724-Methylmorpholine2 回HCID 62365Isobutyl chloroformateHCID 443297Hydroxyamine hydrochlorideHCID 69778494(3R)-6-cyclohexyl-3-(3-{[3-(4-morpholinyl)-1-azetidinyl]carbonyl}-1,2,4-oxadiazol-5-yl)hexanoic acid trifluoroacetate

生成物 1

HCID 10114766(3R)-6-Cyclohexyl-N-hydroxy-3-(3-{[3-(4-morpholinyl)-1-azetidinyl]carbonyl}-1,2,4-oxadiazol-5-yl)hexanamide収率 12.4%

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

反応条件

温度
0 °C

実験手順

A solution of (3R)-6-cyclohexyl-3-(3-{[3-(4-morpholinyl)-1-azetidinyl]carbonyl)1,2,4-oxadiazol-5-yl)hexanoic acid trifluoroacetate (Preparation 28) (1173 mg, 2.70 mmol) and N-methylmorpholine (327 μl, 2.97 mmol) in N,N-dimethylformamide (25 ml) was cooled to 0° C., treated dropwise with isobutyl chloroformate (386 μl, 2.97 mmol) and stirred under a nitrogen atmosphere at 0° C. for 45 minutes. Hydroxylamine hydrochloride (564 mg, 8.11 mmol) was then added followed by further N-methylmorpholine (891 μl, 8.11 mmol) and the mixture was stirred for 18 hours being allowed to warm to room temperature over this time. The solvent was removed under reduced pressure and the residue dissolved in a saturated aqueous solution of sodium carbonate. The pH of the solution was adjusted to 9 by dropwise addition of acetic acid. Water was added (75 ml) and the product was then extracted with ethyl acetate (×2). The combined organic phases were washed with brine, dried over anhydrous sodium sulphate, filtered and the solvent removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a gradient system of dichloromethane:methanol:0.88 ammonia (90:10:1) then dichloromethane:methanol:0.88 ammonia (80:20:2). The product was further purified by HPLC to afford the title compound as a white solid (151 mg)

後処理

  1. stirringthe mixture was stirred for 18 hours
  2. temperatureto warm to room temperature over this time
  3. customThe solvent was removed under reduced pressure
  4. dissolutionthe residue dissolved in a saturated aqueous solution of sodium carbonate
  5. additionThe pH of the solution was adjusted to 9 by dropwise addition of acetic acid
  6. additionWater was added (75 ml)
  7. extractionthe product was then extracted with ethyl acetate (×2)
  8. washThe combined organic phases were washed with brine
  9. dry with materialdried over anhydrous sodium sulphate
  10. filtrationfiltered
  11. customthe solvent removed under reduced pressure
  12. customThe residue was purified by column chromatography on silica gel eluting with a gradient system of dichloromethane
  13. customThe product was further purified by HPLC

出典と根拠

ORDレコード
ord-c34e058bfd144f2c834a8afe00fadf40
出典データセット
uspto-grants-2002_09
特許番号
US06448278B2

反応ノート

読み込み中…